Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEDAPAP vs MICRAININ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
Management of moderate to moderately severe pain where an opioid analgesic is required
Tension headache,Migraine (off-label),Muscle contraction headache
1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In patients with creatinine clearance <30 m L/min, the half-life may be prolonged to 10-15 hours, requiring dose adjustment.
Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours
Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized primarily via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose. Hepatic metabolism to inactive metabolites, followed by biliary and fecal elimination, accounts for the remaining 30-40%. Less than 5% is excreted unchanged in feces.
Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10%
Approximately 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
70-80% bound to albumin
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. Higher Vd is observed in obesity (up to 1.5 L/kg).
0.3-0.5 L/kg; indicates moderate distribution into total body water
Oral: 75-85% due to first-pass metabolism. Intramuscular: 90-100%. Intravenous: 100%.
Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100%
GFR 30-50 m L/min: Use with caution, maximum 4 tablets per day. GFR <30 m L/min: Contraindicated due to butalbital accumulation.
Not studied; use caution with Cr Cl <30 m L/min. Avoid if severe renal impairment (Cr Cl <15 m L/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%, maximum 3 tablets per day. Child-Pugh C: Contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor.
Not recommended for patients under 12 years of age.
Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred.
Initiate at lowest effective dose (1 tablet every 6 hours); monitor for excessive sedation and cognitive impairment.
Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function.
Addiction, Abuse, and Misuse: SEDAPAP exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation and dose titration. Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can cause fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. Cytochrome P450 3A4 Interaction: Concomitant use with CYP3A4 inhibitors may increase hydrocodone levels and prolong adverse effects. Concomitant use with CYP3A4 inducers may decrease efficacy. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity (due to acetaminophen); opioid-induced hyperalgesia; withdrawal; risks of use in patients with head injuries, impaired consciousness, or increased intracranial pressure; use in patients with gastrointestinal conditions including paralytic ileus; use in patients with severe renal or hepatic impairment; use in elderly, cachectic, or debilitated patients; use in patients with pulmonary disease; use in patients with biliary tract disease; use in patients with acute pancreatitis; use in patients with CNS depression; use in patients with toxic psychosis; use in patients with known or suspected surgical abdomen; use in patients with urinary retention; use in patients with prostatic hypertrophy; use in patients with urethral stricture; use in patients with hypothyroidism; use in patients with Addison's disease; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with seizures or seizure disorders; use in patients with substance abuse history; driving and operating machinery; use in pregnancy; use in lactation.
Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease.
Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. High-fat meals may delay absorption but not clinically significant. No specific food restrictions.
Avoid excessive caffeine intake from coffee, tea, soda, or chocolate as it may increase caffeine-related side effects. Grapefruit juice may potentiate effects; limit consumption. Alcohol increases risk of drowsiness and hepatotoxicity.
First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities, cardiac defects, developmental delay), neonatal hemorrhage due to vitamin K deficiency (valproate), and withdrawal syndrome. Acetaminophen carries minimal risk.
MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage.
Both valproate and acetaminophen are excreted into breast milk. Valproate M/P ratio approximately 0.05-0.1; infant serum levels low but potential for hepatotoxicity and thrombocytopenia. Acetaminophen M/P ratio ~1.0, considered safe in therapeutic doses. Caution advised with valproate; monitor infant for jaundice, bruising, and sedation.
Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital.
Valproate: Dose may need reduction due to increased clearance (plasma levels decrease 30-50% in late pregnancy); monitor serum levels and adjust to maintain therapeutic concentration. Acetaminophen: No dose adjustment required in pregnancy; standard dosing recommended.
No specific pharmacokinetic data for MICRAININ during pregnancy. Pregnancy can alter metabolism of acetaminophen and caffeine. Butalbital clearance may increase due to enhanced hepatic metabolism. However, dose adjustments are not typically recommended. Use the lowest effective dose for the shortest duration.
SEDAPAP is a combination product containing an opioid (codeine or hydrocodone) and acetaminophen. Avoid exceeding 3 grams/day of acetaminophen to prevent hepatotoxicity. Monitor respiratory depression, especially in opioid-naive patients and those with sleep apnea. Use with caution in hepatic impairment, ethanol use disorder, and in patients on other CNS depressants. Administer with food to reduce GI upset.
MICRAININ is a fixed-dose combination of butalbital, acetaminophen, and caffeine, used for tension-type headache. Butalbital is a barbiturate with abuse potential; limit quantity prescribed. Acetaminophen hepatotoxicity risk with >3000 mg/day. Caffeine may exacerbate anxiety or insomnia. Avoid in porphyria, severe hepatic impairment, or history of substance abuse. Contraindicated with MAOIs.
Do not exceed recommended dose; too much acetaminophen can cause liver damage.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food or milk if stomach upset occurs.,Report any difficulty breathing, severe constipation, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.,Do not stop suddenly after prolonged use to avoid withdrawal symptoms.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol while taking this medication.,Do not exceed 4000 mg acetaminophen per day from all sources.,This medication can be habit-forming; do not share with others.,May cause drowsiness; avoid driving or operating machinery until you know how it affects you.,Report signs of liver injury: yellowing skin/eyes, dark urine, abdominal pain.,Do not use for more than 5 days per week to avoid rebound headaches.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEDAPAP vs MICRAININ, answered by our medical review team.
SEDAPAP is a Barbiturate Combination Analgesic that works by SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.. MICRAININ is a Barbiturate Combination Analgesic that works by MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEDAPAP and MICRAININ depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEDAPAP is: 1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.. The standard adult dose of MICRAININ is: 2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEDAPAP and MICRAININ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEDAPAP is classified as Category C. First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities. MICRAININ is classified as Category C. MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, par. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.